NEW YORK, NY, Feb 21, 2014 (Marketwired via COMTEX) — Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
http://www.publicwire.com/2014/02/21/nvlx-move-over-celgene-here-comes-nuvilex-and-27-million-to-advance-its-pancreatic-cancer-clinical-trials/
No comments:
Post a Comment